Investment analysts at StockNews.com initiated coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock.
Aptevo Therapeutics Stock Performance
APVO opened at $0.36 on Wednesday. Aptevo Therapeutics has a twelve month low of $0.28 and a twelve month high of $21.56. The company has a 50-day moving average price of $0.38 and a 200 day moving average price of $1.57.
Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) last announced its earnings results on Thursday, August 8th. The biotechnology company reported ($1.67) EPS for the quarter, beating analysts’ consensus estimates of ($1.93) by $0.26. As a group, equities analysts forecast that Aptevo Therapeutics will post -4.3 EPS for the current fiscal year.
Institutional Investors Weigh In On Aptevo Therapeutics
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Featured Articles
- Five stocks we like better than Aptevo Therapeutics
- What Is WallStreetBets and What Stocks Are They Targeting?
- 3 Leveraged ETFs to Multiply Returns
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- A Tale of Two Titans: Unveiling the Value in Baidu and JD.com
- What is a Low P/E Ratio and What Does it Tell Investors?
- Is the AI-Capable iPhone 16 the Start of a Sales Super-Cycle?
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.